前列腺癌
生物
前列腺
DNA甲基化
疾病
外显子组
色丛
外显子组测序
基因
癌症研究
遗传学
计算生物学
癌症
医学
病理
突变
PCA3系列
基因表达
作者
Michael Fraser,Veronica Y. Sabelnykova,Takafumi N. Yamaguchi,Lawrence E. Heisler,Julie Livingstone,Vincent Huang,Yu-Jia Shiah,Fouad Yousif,Xihui Lin,Andre Masella,Natalie S. Fox,Michael Xie,Stephenie D. Prokopec,Alejandro Berlín,Emilie Lalonde,Musaddeque Ahmed,Dominique Trudel,Xuemei Luo,Tim Beck,Alice Meng
出处
期刊:Nature
[Nature Portfolio]
日期:2017-01-01
卷期号:541 (7637): 359-364
被引量:564
摘要
Prostate tumours are highly variable in their response to therapies, but clinically available prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 whole-genome sequences and 277 additional whole-exome sequences from localized, non-indolent prostate tumours with similar clinical risk profiles, and carried out RNA and methylation analyses in a subset. These tumours had a paucity of clinically actionable single nucleotide variants, unlike those seen in metastatic disease. Rather, a significant proportion of tumours harboured recurrent non-coding aberrations, large-scale genomic rearrangements, and alterations in which an inversion repressed transcription within its boundaries. Local hypermutation events were frequent, and correlated with specific genomic profiles. Numerous molecular aberrations were prognostic for disease recurrence, including several DNA methylation events, and a signature comprised of these aberrations outperformed well-described prognostic biomarkers. We suggest that intensified treatment of genomically aggressive localized prostate cancer may improve cure rates.
科研通智能强力驱动
Strongly Powered by AbleSci AI